The cingulate cortex occupies a medial position in the cerebral hemispheres and extends from the frontal lobe (anterior cingulate cortex, ACC) through the midcingulate region (MCC) to the ...
Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of ...
Researchers from the Icahn School of Medicine at Mount Sinai have uncovered the first direct evidence that deep brain stimulation (DBS) can remodel white matter pathways in the brain and alter ...
Biopharma company Cingulate announced a joint commercialization agreement with Indegene this week, which pushes forward Cingulate’s lead drug candidate for attention deficit/hyperactivity disorder ...
Lead asset CTx-1301, Cingulate’s twist on methylphenidate, is set to enter phase 3 by the end of the year. (Nasdaq) Can drug delivery technology equip Cingulate to win market share from Johnson & ...
Cingulate Inc. has been granted a European patent for its ADHD treatment, CTx-1301. Following the patent news, Cingulate's stock has surged by 302.9%, reflecting strong market confidence in the ...
Cingulate Inc. (NASDAQ:CING) is one of the best NASDAQ growth stocks to buy and hold forever. On March 18, Cingulate reported its financial results for Q4 and the full year 2025, highlighting the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results